This #LiverAwarenessMonth, we're highlighting #Axiomer #RNAEditing and its applications in cholestatic liver diseases. Learn more: bit.ly/4i5SpOM
Curious about how #Axiomer works? Visit: bit.ly/4iiweDL
#CholestaticDisease #LiverHealth
#BiliaryAtresia (BA) is the leading cause of liver transplantation in children. This #LiverAwarenessMonth, we’re highlighting the urgent need for new options for patients and families affected by BA.
Learn more: bit.ly/4ynZ9ME
#RareDisease #RNAEditing #Axiomer
This #LiverAwarenessMonth, we’re raising awareness of #BiliaryAtresia (BA), a rare liver disease that affects newborns and young children.
For more information about BA, visit our website: bit.ly/3VykIN6
#RareDisease #PediatricLiverDisease #Axiomer #RNAEditing
On Sept 30 at 11a ET join our virtual Investor and Analyst educational event “NTCP Modulation in Biliary Atresia via Liver-Targeted RNA Editing”.
For additional information about the event and to register, visit: proqr.com/events
#Axiomer #RNAEditing @ProQR
ALT cover slide with text “NTCP Modulation in Biliary Atresia via Liver-Targeted RNA Editing” dated September 30, 2026
Axiomer Insights: Our team published findings in Scientific Reports on preclinical liver models for ADAR-mediated RNA editing. Monica from our research team discusses how model selection can inform translatability for our #Axiomer #RNAEditing platform.
bit.ly/3UWJLZz
ProQR welcomes Chris Hart as Chief Data & AI Officer and Thomas Wolf as Strategic AI Advisor to the Board. Their appointments support our strategy to apply AI across discovery and development. AX-0811, the first AI-discovered ProQR program is now in clinical trials.
#Axiomer
Meet Anne Geert from our CMC team! He is responsible for producing the drug substances used in our preclinical and clinical programs. He also helps organize the ProQR conference.
Learn more: bit.ly/4gjPtgA
#Axiomer #TeamProQR
Today we released our Q2 2026 financial results and provided a business update. Read the full press release on our website: bit.ly/45pX5Ic
$PRQR #Biotech #Axiomer #RNAEditing
ProQR has made available a video featuring it’s Management Team discussing the Phase 1 AX-0810 data, the clinical validation of the #Axiomer #RNAEditing platform, AX-0811 and next steps with NTCP.
Watch here: bit.ly/3QZpq4o
Last week, ProQR co-founder Dinko Valerio joined the team to reflect on ProQR’s journey from an ambitious idea to advancing our #Axiomer #RNAEditing platform in the clinic.
We are grateful to Dinko for his contributions over the years and for sharing his passion and insights.
